Manipal Health Enterprises Limited (MANIPALHOS)
₹676.50 -0.14% இன்றைய முடிவு விலை
சுருக்கம்
Manipal Health Enterprises Limited closed at ₹676.50 on 12 Nov 2026, with an RSI(14) of 53.0. On the daily chart it is in a range, with a technical score of 54/100 (neutral). In the quarter ended June 2026, revenue grew 28.2% and net profit fell 8.3% from a year earlier. The board meets on 13 Nov 2026 to consider the Q2 FY27 results. Data as of 12 Nov 2026.
விலை
- விலை
- ₹676.50
- நாள் மாற்றம்
- -0.14%
- சந்தை மதிப்பு
- ₹88,985 கோடி
- 52-வார வரம்பு
- ₹597.00 – ₹815.00
- 52-வார உச்சத்திலிருந்து
- -16.99%
- 52-வார தாழ்விலிருந்து
- +13.32%
பங்கு உரிமைசெப். 2026
- புரமோட்டர்கள்
- 72.08%
- FII-கள்
- 3.50%
- DIIs
- 7.18%
செப்டம்பர் 2026 உடன் முடிவடைந்த காலாண்டுக்கான பங்குதாரர் விவரம்; சதவீதப் புள்ளிகளில் மாற்றங்கள்.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 13 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- Q1 FY27, தாக்கல் செய்யப்பட்டது 20 ஆக. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 20 ஆக. 2026
நிதிநிலை12 நவ. 2026
- YoY காலாண்டு விற்பனை வளர்ச்சி
- 28.2%
- YoY காலாண்டு லாப வளர்ச்சி
- -8.3%
Latest quarter Jun 2026 · Standalone
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 62.29% எதிர் சராசரி 54.03%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 1.3×
- பல்க் & பிளாக் டீல்கள்
- 60 நாட்களில் 2
டெக்னிக்கல்ஸ்12 நவ. 2026
- போக்கு
- வரம்பு
- தொழில்நுட்ப மதிப்பெண்
- 54/100 · நடுநிலை
- MACD
- ஏற்றத்துக்கு சாதகமான (bullish)
- RSI (14)
- 53.00
- ADX (14)
- 17.27
- SuperTrend
- இறக்கத்துக்கு சாதகமான (bearish)
- 20-நாள் SMA-உடன் ஒப்பீடு
- +4.70%
- 50-நாள் SMA-உடன் ஒப்பீடு
- -1.92%
- அருகிலுள்ள சப்போர்ட்
- ₹662.35
- அருகிலுள்ள ரெசிஸ்டன்ஸ்
- ₹702.00
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 13 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Manipal Health Enterprises Limited-இன் இயக்குநர் குழுக் கூட்டம் 13 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, Q1 FY27, Manipal Health's revenue was ₹1,048 Cr (+28.2% year on year, +8.4% on the previous quarter), and net profit ₹116 Cr (-8.3% year on year); the operating margin was 23.9%.
| Q1 FY27 (₹ கோடி) | மதிப்பு | YoY Q1 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹1,048 | +28.2% | +8.4% |
| செயல்பாட்டு லாபம் | ₹250 | +12.1% | +12.1% |
| நிகர லாபம் | ₹116 | -8.3% | +25.6% |
| EPS (₹) | 0.98 | -10.1% | +25.6% |
| செயல்பாட்டு லாப வரம்பு | 23.9% | — | — |
MANIPALHOS delivery percentage and bulk deals
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 62.29% of the MANIPALHOS shares traded on NSE were taken to delivery, against the stock's own 20-session average of 54.03%. That is close to its usual level. 2 bulk or block deals were reported in MANIPALHOS in the last 60 days: ₹120 Cr bought and ₹120 Cr sold.
கடந்த 5 அமர்வுகளில் டெலிவரி: 49.9% · 50.6% · 69.9% · 67.6% · 62.3%
| தேதி | பக்கம் | எதிர்தரப்பு | மதிப்பு | விலை | அளவு | வகை |
|---|---|---|---|---|---|---|
| 21 அக். | விற்க | Prazim Trading And Investment Company Private Limited | ₹119.57 கோடி | ₹630.00 | 1,897,973 | பிளாக் |
| 21 அக். | வாங்கு | Pi Opportunities Aif V Llp | ₹119.57 கோடி | ₹630.00 | 1,897,973 | பிளாக் |
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Promoter group entity MEMG International India Private Limited submitted disclosures under SEBI Takeover Regulations regarding the creation of a pledge over equity shares of Manipal Health Enterprises Limited. The disclosure dated October 30, 2026, details encumbrance activities concerning promoter holdings. While specific newly pledged share quantities in the truncated section are not fully disclosed, prior encumbered holdings noted for promoter Manipal Global Health Services stood at 23,21,47,755 shares (17.43% of share capital on a fully diluted basis).
- Disclosure filed under Regulation 31(1) and 31(2) of SEBI SAST Regulations, 2011.
- Pledge created over shares by promoter group entity MEMG International India Private Limited.
- Manipal Global Health Services (Promoter) holding already encumbered reported at 23,21,47,755 shares (17.43% on a fully diluted basis).
- Reporting date to exchanges recorded as October 30, 2026.
Manipal Health Enterprises Limited has announced that it will declare its Q2 FY27 and H1 FY27 financial results on Friday, November 13, 2026. Following the announcement, the management team, including the MD & CEO, Group CFO, and COO, will host an earnings conference call at 18:00 IST on the same day. In the previous quarter (Q1 FY27 / Jun 2026), the company posted a revenue of Rs 1,048.3 crore and a net profit of Rs 115.53 crore. The company currently operates 50 hospitals with over 13,400 licensed beds across 14 States and Union Territories.
- Earnings call scheduled for November 13, 2026, at 18:00 hrs IST for Q2 and H1 FY27 results
- Call will be hosted by MD & CEO Dilip Jose, Group CFO Sameer Agarwal, and COO Karthik Rajagopal
- Company footprint comprises 50 hospitals with over 13,400 licensed beds across 14 States & UTs
- Previous reported revenue stood at Rs 1,048.3 crore with Rs 115.53 crore net profit in Jun 2026
Manipal Health Enterprises Limited has entered into a 30-year long-term land lease agreement with SGX-listed Thakral Corporation's subsidiary, TIL Investments Pvt Ltd. The deal secures approximately 3.5 acres of land in Gurugram, Delhi NCR, to develop and operate a multi-speciality hospital. The project will be developed in phases, with the first phase planned to add up to 500 beds. This addition builds on Manipal's existing network of 50 hospitals with over 13,400 licensed beds.
- Leased approximately 3.5 acres of land in Gurugram, Delhi NCR for an initial period of ~30 years
- Phase 1 development expected to add up to 500 beds
- Expands upon existing operational network of 50 hospitals and over 13,400 licensed beds
- Partnered with TIL Investments Pvt Ltd, an Indian subsidiary of SGX-listed Thakral Corporation
Manipal Health Enterprises Limited has executed a lease deed with TIL Investments Private Limited for land located in Kherki Daula, Gurugram, Haryana. The lease has been secured for a tenure of 29 years and 11 months to construct, operate, manage, and maintain a new hospital. The counterparty is an unrelated party, and the transaction is not a related-party deal. Financial terms, capex budget, and proposed bed capacity were not disclosed in the filing.
- Lease tenure agreed for 29 years 11 months with TIL Investments Private Limited
- Land situated at Village Kherki Daula, Tehsil Manesar, District Gurugram, Haryana
- Land secured for constructing, operating, managing, and maintaining a hospital
- Transaction is not with a related party; no special governance rights conferred
Manipal Health Enterprises Limited disclosed that its subsidiary, Manipal Hospitals Eastern India Private Limited, received two tax demand orders from Kolkata GST authorities. The first order confirms a demand of ₹3,77,52,668 with a penalty of ₹37,75,266 for FY 2019-20 relating to ITC and outward supplies. The second order confirms a demand of ₹4,22,95,004 alongside an equivalent penalty of ₹4,22,95,004 for FY 2021-22 regarding supplies of drugs and consumables to inpatients. Total demand and penalties stand at approximately ₹12.61 cr, which the company states has no material operational impact and will be appealed.
- First order confirms a tax demand of Rs 3,77,52,668 and a penalty of Rs 37,75,266 for FY 2019-20
- Second order confirms a tax demand of Rs 4,22,95,004 plus a penalty of Rs 4,22,95,004 for FY 2021-22
- Total confirmed tax demands amount to Rs 8.00 cr and total penalties amount to Rs 4.61 cr (cumulative exposure Rs 12.61 cr)
- Orders were received by the subsidiary on August 14, 2026, and September 11, 2026
Manipal Health Enterprises Limited concluded its 16th AGM on September 29, 2026, where 10 of 11 proposed resolutions were approved by shareholders. Notably, Resolution 9 regarding an Upside Sharing Arrangement between Manipal Research & Management Services International and TPG SG Magazine Pte. Ltd. was defeated, receiving 61.99% votes against (6,68,85,785 votes against vs 4,10,16,249 in favour). Other key proposals passed, including Price Waterhouse Chartered Accountants LLP's appointment as statutory auditor (99.99% approval) and special governance rights under the Articles of Association for Temasek and MGHS Groups (94.45% approval).
- 10 out of 11 resolutions approved at the 16th AGM held on September 29, 2026
- Resolution 9 (Upside Sharing Arrangement with TPG) rejected with 61.9875% votes cast against
- PwC appointed as statutory auditor with 99.9999% votes in favour (1,20,18,09,921 votes)
- Amendments to Articles of Association granting rights to Temasek and MGHS Groups passed with 94.4546% approval
- Total voter turnout represented 91.3663% of outstanding shares (1,20,18,10,823 votes polled)
Manipal Health Enterprises Limited reported the proceedings of its 16th Annual General Meeting held on September 29, 2026. The Chairman highlighted FY26 revenue growth of 25.4% to ₹10,336 crores, with operating EBITDA of ₹2,644 crores (25.6% margin) and PAT of ₹917 crores. The network expanded to 49 hospitals with over 13,000 licensed beds, supported by the Sahyadri Hospitals acquisition (10 hospitals, 1,606 beds) and two new greenfield Bengaluru facilities. A total of 11 resolutions—including ESOP 2024 ratification, auditor appointments, and governance rights for Temasek and MGHS Groups—were tabled for voting.
- FY26 revenue increased 25.4% YoY to ₹10,336 crores, compared to ₹8,242 crores in the previous year
- Operating EBITDA reached ₹2,644 crores at a 25.6% margin, while PAT stood at ₹917 crores
- Operated 49 hospitals with >13,000 licensed beds across 14 States/UTs as of March 31, 2026
- Sahyadri Hospitals acquisition added 10 hospitals and 1,606 licensed beds
- Shareholders voted on 11 resolutions including ESOP 2024 and special nomination rights to Temasek and MGHS Groups
Manipal Health Enterprises Limited has fully redeemed outstanding listed Non-Convertible Debentures (NCDs) worth ₹5,310 crore issued by its subsidiary, Manipal Hospitals Private Limited, utilizing its IPO proceeds. The redemption covers principal, accrued interest, and early redemption costs in accordance with its July 31, 2026 prospectus objects. This debt reduction is aimed at significantly strengthening the balance sheet and lowering future interest burdens. In Q1 FY27, the company reported consolidated revenue growth of 38.1% year-on-year to ₹3,091 crore and an EBITDA of ₹749 crore.
- Full redemption of outstanding listed NCDs with nominal value of ₹5,310 crore
- Funded via IPO proceeds in line with the prospectus dated July 31, 2026
- Q1 FY27 revenue stood at ₹3,091 crore (up 38.1% YoY) with EBITDA at ₹749 crore (up 26.4% YoY)
- Q1 FY27 PAT reported at ₹243 crore, with adjusted PAT reaching ₹332 crore
Manipal Health Enterprises Limited has fully redeemed outstanding listed non-convertible debentures (NCDs) worth Rs 5,310 crore issued by its wholly owned subsidiary, Manipal Hospitals Private Limited. The redemption, which includes accrued interest and early prepayment charges, was funded using the proceeds from its recent Initial Public Offering. This utilization aligns with the stated objects of the offer outlined in its Prospectus dated July 31, 2026. The full repayment significantly deleverages the consolidated balance sheet.
- Full redemption of Rs 5,310 crore nominal value listed NCDs issued by subsidiary Manipal Hospitals Private Limited
- Funded via relevant portion of proceeds raised through the company's Initial Public Offering
- Redemption includes nominal value, accrued interest, and applicable early prepayment costs
- Executed strictly as per the objects of the offer detailed in the Prospectus dated July 31, 2026
Manipal Health Enterprises Limited has issued a communication under Regulation 36(1)(b) of SEBI LODR providing the weblink to its Annual Report for FY 2025-26 and the Notice of its 16th Annual General Meeting (AGM). The AGM is scheduled to take place on Tuesday, September 29, 2026, at 11:00 a.m. IST via Video Conferencing / Other Audio-Visual Means. The physical dispatch of the weblink is directed to shareholders whose email addresses are not registered with the company or depository participants.
- 16th Annual General Meeting scheduled for Tuesday, September 29, 2026, at 11:00 a.m. IST
- AGM to be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM)
- Annual Report for FY 2025-26 and AGM notice made available on the company website and exchange portals
- Communication dispatched to unregistered shareholders via RTA KFin Technologies Limited
Manipal Health Enterprises released the transcript of its Q1 FY27 earnings call, reporting consolidated revenue of ₹3,091 crore, up over 38% YoY. Network EBITDA reached ₹749 crore (+26% YoY) with an operating margin of 24.2% (25% excluding Sahyadri Hospitals). Growth was driven by a 39% rise in inpatient volumes and 26% in OP volumes, with network occupancy at 65% and ALOS at 2.7 days. The company has expanded its network to over 13,000 beds, launched its 50th hospital in Bangalore, and maintains a low net debt-to-EBITDA ratio of 0.9x post-IPO.
- Q1 revenue grew 38% YoY to ₹3,091 crore with Network EBITDA reaching ₹749 crore (24.2% margin)
- ARPOB ex-Sahyadri rose 9% YoY to ₹77,200/day, with network occupancy improving by 290 bps to 65%
- Sahyadri Hospitals delivered ₹332 crore in revenue and ₹58 crore EBITDA (17% margin vs 25% ex-Sahyadri)
- Digital revenue contributed ₹710 crore, accounting for 23% of total revenue in Q1
- Total network capacity stands above 13,000 beds following 103 brownfield beds in Nashik and a new 300-bed unit in Electronic City
Manipal Health Enterprises Limited has published the audio recording of its earnings conference call conducted with analysts and institutional investors on August 21, 2026, at 11:00 AM. The recording has been uploaded on the company's website in compliance with SEBI LODR Regulations 30 and 46. In the preceding June 2026 quarter, the company reported revenue of ₹1,048.30 cr and net profit of ₹115.53 cr.
- Earnings conference call with analysts and investors conducted on August 21, 2026 at 11:00 AM
- Audio recording uploaded to the company website pursuant to SEBI LODR Regulations 30 and 46
- Company posted revenue of ₹1,048.30 cr and operating profit of ₹250.05 cr in the Jun 2026 quarter
Manipal Health Enterprises has approved the appointment of Price Waterhouse Chartered Accountants LLP as its statutory auditor for a 5-year tenure (FY27 to FY31), succeeding BSR & Co. LLP upon tenure completion. The Board also approved amendments to the Articles of Association granting Temasek Group right to nominate up to 3 directors and MGHS Group up to 2 directors, provided each holds at least 6% equity. Additionally, the Board noted an upside sharing payment between TPG and promoter entity MRMSI, subject to shareholder approval at the AGM scheduled for September 29, 2026.
- Appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for a 5-year term from the 16th AGM to 21st AGM.
- AoA amendment enabling Temasek Group to nominate up to 3 Directors and 3 Executive Committee members subject to a minimum 6% holding.
- AoA amendment enabling MGHS Group to nominate up to 2 Directors and 2 Executive Committee members subject to a minimum 6% holding.
- Noted upside share amount payable by TPG to promoter group entity MRMSI under March 16, 2026 agreement, subject to Reg 26(6) shareholder approval.
- 16th Annual General Meeting scheduled for September 29, 2026.
Manipal Health Enterprises reported a 38.1% YoY increase in revenue from operations to ₹3,091 crore for Q1 FY27 in its first earnings report post-listing. EBITDA grew 26.4% YoY to ₹749 crore with a 24.2% margin (adjusted EBITDA up 29.7% YoY). Reported PAT stood at ₹243 crore, while PAT adjusted for ₹89 crore post-tax interest on Sahyadri acquisition NCDs rose 30.9% YoY to ₹332 crore. Network occupancy improved by 290 bps YoY to 65.0%, and ARPOB (excluding Sahyadri) grew 8.7% YoY to ₹77,200 per day.
- Revenue from operations grew 38.1% YoY to ₹3,091 crore in Q1 FY27 compared to ₹2,238 crore in Q1 FY26.
- EBITDA increased 26.4% YoY to ₹749 crore; adjusted EBITDA (ex-one-off) grew 29.7% YoY.
- Adjusted PAT reached ₹332 crore (up 30.9% YoY), excluding ₹89 crore post-tax interest on Sahyadri NCD debt.
- Occupancy expanded 290 bps YoY to 65.0%, with inpatient volumes up 38.8% YoY.
- Sahyadri Hospitals contributed ₹332 crore in revenue (+12.8% YoY) and ₹58 crore in EBITDA (+18.7% YoY).
Manipal Health Enterprises Limited approved its unaudited financial results for the quarter ended June 30, 2026, with an unmodified review report. The Board recommended the appointment of M/s Price Waterhouse Chartered Accountants LLP as statutory auditors for a 5-year term (FY27 to FY31) replacing BSR & Co. LLP. Additionally, the Board proposed an amendment to the Articles of Association allowing Temasek Group to nominate up to 3 directors and MGHS Group up to 2 directors, provided each holds at least 6% equity. The 16th Annual General Meeting is scheduled for September 29, 2026.
- Approved standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
- Appointed M/s Price Waterhouse Chartered Accountants LLP for a 5-year term from the 16th AGM (2026) to the 21st AGM (2031).
- Proposed AoA amendment granting Temasek Group up to 3 board seats and MGHS Group up to 2 seats, subject to maintaining a minimum 6% equity stake.
- Noted upside sharing arrangement between TPG and MRMSI dated March 16, 2026, requiring shareholder approval under SEBI Reg 26(6).
- Scheduled the 16th Annual General Meeting on Tuesday, September 29, 2026.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
